An FDA panel backed Amarin's fish oil drug. Here's a detailed breakdown

An FDA panel backed Amarin's fish oil drug. Here's a detailed breakdown

STAT Plus: An FDA advisory panel is reviewing Amarin’s fish oil drug. Follow along for frequent updates

By ADAM FEUERSTEIN AND MATTHEW HERPER

AMARIN

STAT is monitoring the meeting to discuss the heart-protective data on Vascepa, a drug derived from fish oil that is marketed by Amarin.

READ MORE